EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model?

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Terragni, Rossella ^a,b   Casadei Gardini, Andrea ^c   Sabattini, Silvia ^d   Bettini, Giuliano ^d   Amadori, Dino ^c   Talamonti, Chiara ^d   Vignoli, Massimo ^e   Capelli, Laura ^c   Saunders, Jimmy H ^b   Ricci, Marianna ^b   Ulivi, Paola ^b  

^a Veterinary Oncology Center ^*  (Italy)

^b GHENT UNIVERSITY   (Belgium)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Petcare Veterinary Association   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PRIMER DNA;

ANIMAL TISSUE; ARTICLE; CANCER CLASSIFICATION; DISEASE MODEL; DOG; FEMALE; KRAS GENE; MALE; NONHUMAN; POINT MUTATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH ADENOMA; STOMACH CARCINOMA; STOMACH EPITHELIUM; STOMACH TUMOR; ADOLESCENT; ANIMAL; CHILD; GENETICS; HUMAN; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PROTO ONCOGENE;

ADOLESCENT; ANIMALS; BASE SEQUENCE; CHILD; DISEASE MODELS, ANIMAL; DNA PRIMERS; DOGS; FEMALE; GENES, ERBB-2; GENES, RAS; HUMANS; MALE; MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84898637547     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085388     Document Type: Article

References (43)

1. Withrow SJ (2007) Cancer of the gastrointestinal tract. In: Withrow SJ, Wail DM. Withrow and MacEwen's Small Animal Clinical Oncology. 4th edition. St. Louis, Missouri: Elsevier Saunders. 480-482.
2. Swann HM, Holt DE (2002) Canine gastric adenocarcinoma and leiomyosarcoma: a retrospective study of 21 cases (19 (Pubitemid 34232794)
3. Patnaik AK, Hurvitz AI, Jhonson G (1978) Canine gastric adenocarcinoma. Vet Pathol 15:600-607. (Pubitemid 9004792)
4. Sullivan M, Lee R, Fisher EW, Nash AS, McCandlish IA (1987) A study of 31 cases of gastric carcinoma in dogs. Vet Rec 120:79-83.
5. Scanziani E, Giusti AM, Gualtieri M, Fonda D (1991) Gastric Carcinoma in the Belgian shepherd dog. J Small Anim Pract 32:465-469.
6. Hicks DG, Whitney-Miller C (2011) HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol 19:506-508.
7. Lorenzen S, Lordick F (2011) How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? Curr Opin Oncol 23:396-402.
8. Rowinsky EK (2004) The erbB family: target for Therapeutic Develoment Against Cancer and Therapeutic Strategies Using Monoclonal Antibodies and Tyrosine Kinase Inhibitors. Annu Rev Med 55:433-457. (Pubitemid 38316736)
9. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529.
10. Okines AFC, Cunningham D (2010) Trastuzumab ingastric cancer. EurJCancer 46:1949-1959.
11. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697.
12. Lee S, De Boer WB, Fermoyle S, Platten M, Kumarasinghe MP (2011) Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 59:832-840.
13. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, et al. (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75:1418-1425.
14. Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, et al. (2003) Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 1:438-445. (Pubitemid 37413607)
15. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, et al. (2009) Phase II study study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 101:1261-1268.
16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2008) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345.
17. Wang J, Yang H, Shen Y, Wang S, Lin D, et al. (2013) Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Cancer Biomark 13:89-97.
18. Gama A, Gärtner F, Alves A, Schmitt F (2009) Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Res Vet Sci 87:432-437.
19. Shiomitsu K, Johnson CL, Malarkey DE, Pruitt AF, Thrall DE (2009) Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumors. Vet Comp Oncol 7:106-114.
20. Bergkvist GT, Yool DA (2010) Epidermal growth factor receptor as a therapeutic target in veterinary oncology. Vet Comp Oncol 9:81-94.
21. Higgins RJ, Dickinson PJ, Lecouteur RA, Bollen AW, Wang H, et al. (2010) Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. J Neurooncol 98:49-55.
22. Sabattini S, Mancini FR, Marconato L, Bacci B, Rossi F, et al. (2012) EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival. Vet Comp Oncol In press.
23. Martin De Las Mulas J, Ordá S, Millán Y, Fernandez-Soria V, Ramón Cajal S (2003) Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res Treat 80:363-367. (Pubitemid 37046761)
24. Hsu WL, Huang HM, Liao JW, Wong ML, Chang SC (2009) Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. Vet J 180:116-123.
25. Ressel L, Puleio R, Loria GR, Vannozzi I, Millanta F, et al. (2013) HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome. Res Vet Sci 94:299-305.
26. Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, et al. (2012) Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol 50:200-209.
27. Head KW, Cullen JM, Dubielzig RR, Else RW, Misdorp W, et al. (2003) World Health Organization International Histological Classification of Tumors of Domestic Animals - Histological Classification of Tumors of the Alimentary System of Domestic Animals, 2nd series, vol. X. Washington, DC, Armed Forces Institute of Pathology.
28. Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31-49.
29. Washington K (2010) 7th Edition of the AJCC Cancer Staging Manual: Stomach. Ann Surg Oncol 17:3077-3079.
30. Sassi F, Benazzi C, Castellani G, Sarli G (2010) Molecular-based tumor subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res 6:5.
31. Wang YK, Gao CF, Yun T, Chen Z, Zhang XW, et al. (2011) Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Mol Cytogenet 4:14.
32. Hofmann M, Stoss O, Shi D, Büttner R, Van De Vijver M, et al. (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805. (Pubitemid 351724903)
33. Sautter JH, Hanlon GF (1975) Gastric neoplasms in the dog: a report of 20 cases. J Am Vet Med Assoc 166:691-696.
34. Fonda D, Gualtieri M, Scanziani E (1989) Gastric carcinoma in the dog: a clinicopathological study of 11 cases. J Small Anim Pract 30:353-360.
35. Liu C, Crawford JM (2005) The gastrointestinal tract. In: Kumar V, editor. Pathologic Basis of disease. Philadelphia, PA: Elsevier Saunders. 804-805.
36. Buskens CJ, Hulscher JBF, Van Gulik TM, Ten Kate FJ, Van Lanschot JJB (2006) Histopathologic evaluation of an animal model for Barett's esophagus and adenocarcinoma of the distal esophagus. J Surg Res 135:337-344. (Pubitemid 44414894)
37. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W (2010) HER2 expression in gastric cancer. Rare, heterogeneous and of no prognostic valueconclusions from 924 cases of two independent series. Cell Oncol 32:57-65.
38. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27:1130-1136.
39. Lee HR, Kim JH, Uhm HD, Ahn JB, Rha SY, et al. (1996) Overexpression of cerbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 53:192-197. (Pubitemid 26131941)
40. Chen HC, Chen HJ, Khan MA, Rao ZZ, Wan XX, et al. (2011) Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China. Tumor Biol 32:367-373.
41. Kraegel SA, Gumerlock PH, Dungworth DL, Oreffo VI, Madewell BR (1992) K-ras Activation in non-small cell lung cancer in the dog. Cancer Res 52:4724-4727.
42. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459-465. (Pubitemid 37328850)
43. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909.